Abstract
The combination of geniposide (200 mg/kg), chlorogenic acid (160 mg/kg), and rhubarb polysaccharide (340 mg/kg) exerts the optimal ameliorative effect on metabolic-associated steatotic liver disease (MASLD) in mice. This superior efficacy is achieved by synergistically regulating key nodes of glycolipid and bile acid metabolism, ultimately optimizing therapeutic outcomes.
Introduction
Metabolic-associated steatotic liver disease (MASLD), formerly known as NAFLD, has become a global epidemic closely linked to obesity and type 2 diabetes. Despite its prevalence, specific FDA-approved pharmacological treatments remain elusive. Traditional Chinese Medicine (TCM), specifically the Yinchenhao decoction (YCHT), has been used for centuries to treat liver and gallbladder ailments. However, its complex chemical composition makes standardization and mechanistic clarity difficult. This study aims to transition from traditional herbal formulations to precision medicine by identifying the primary active ingredients and the specific dosage ratio required to maximize therapeutic efficacy while minimizing unnecessary bulk.
Methodology
The researchers employed a multi-stage experimental workflow to determine the optimal component ratio:
- Animal Modeling: C57BL/6 mice were fed a high-fat, high-cholesterol "Western diet" for 8 weeks to induce MASLD.
- Uniform Design (UD): To avoid testing thousands of possible combinations, a statistical "Uniform Design" method was used to evaluate six representative dosage combinations of geniposide, chlorogenic acid, and rhubarb polysaccharides.
- Mathematical Modeling: Stepwise regression analysis was performed on liver enzyme and lipid level data to calculate the theoretical optimal dosage ratio.
- Validation: The calculated optimal mix was compared against single-drug treatments, the original YCHT decoction, and a positive control drug (Obeticholic acid) using techniques such as qRT-PCR and Western Blotting to analyze gene and protein expression (e.g., FXR and CYP7A1).
Results and Discussion
Synergistic Multi-Pathway Regulation
The study confirmed that the three-component mix was significantly more effective than any individual component at the same dose, validating the TCM philosophy of synergy. The optimal combination (200 mg/kg geniposide + 160 mg/kg chlorogenic acid + 340 mg/kg rhubarb polysaccharide) addressed MASLD through three primary mechanisms:
- Improved Insulin Sensitivity: Reduction in blood sugar and liver glycogen accumulation.
- Inhibition of Lipogenesis: Downregulation of fat-synthesis genes such as Fasn and Srebp-1c.
- Bile Acid Homeostasis: Normalization of the BSEP (bile salt export pump) and FXR regulator, alongside the normalization of CYP7A1, which converts cholesterol to bile acid.
Histological and Biochemical Recovery
Treatment with the optimal combination significantly lowered ALT and AST levels, markers of liver damage, compared to the MASLD model group ($P < 0.01$). Histological analysis revealed a drastic reduction in lipid droplet area and improved liver architecture.
Furthermore, the treatment effectively lowered total bile acids (TBA) and bilirubin in the blood, indicating a restoration of the liver's metabolic pathways. Mice treated with the optimal mix showed glucose tolerance and insulin sensitivity levels comparable to those treated with the pharmaceutical control, Obeticholic acid.
Conclusion and Future Directions
While these results are promising in a controlled mouse model, human MASLD presents additional complexities. Future research should explore the role of the gut-liver axis and the microbiome's interaction with these TCM compounds. Additionally, clinical translation will require pharmacokinetic studies to determine human equivalent doses and long-term safety profiles for this purified combination.
Summary updated